SH Profil Institut fur Stoffwechselforschung GmbH Related Content

Professor Freimut Schliess, Director of Science & Innovation, at the Profil Institut für Stoffwechselforschung GmbH, illustrates how dissipating initial scepticism of digital health technologies makes for a thrilling challenge for regulators, manufacturers and clinical researchers alike.

Professor Dr Freimut Schliess, Director of Science & Innovation at the Profil Institut für Stoffwechselforschung GmbH, explores how the MDR will impact clinical trials.

Prof. Dr. Freimut Schliess discusses digital health innovation in Germany, tackling larger public health challenges being faced.

Here, Tatiana Affini Dicenzo and Freimut Schliess discuss bridging the gap between clinical trials and clinical care, specifically exploring if wearables are fit for this purpose.

The importance of continuous real-world monitoring of cardiorespiratory health, including adding value to pivotal clinical trials.

Prof Dr Freimut Schliess, Director of Science & Innovation at the Profil Institut für Stoffwechselforschung GmbH, explores if digital twins are game-changers in clinical research and clinical care.

Prof Dr Freimut Schliess, Director of Science & Innovation at the Profil Institut für Stoffwechselforschung GmbH, shares a vision for remote decentralised clinical trials.

Prof Dr Freimut Schliess, Director of Profil GmbH, discusses how CROs can play a key role for the optimisation of innovation pathways.

RealWorld4Clinic is a new European initiative bringing real-world data to pivotal clinical research and outpatient cardiology care.

When it comes to trustworthy artificial intelligence (AI) in healthcare, Prof Dr Freimut Schliess from Profil GmbH, argues that now is the time to deliver.

Here, the tangible impact on diabetes patients and their care is thoroughly explored via integrated personalised diabetes management (iPDM).

Prof Dr Freimut Schliess, Director, Science & Innovation at Profil GmbH, sheds light on how Clinical Contract Research Organisations are building the digital bridge connecting clinical research and clinical care.

Taking advantage of data and trustworthy collaboration is the way to go when it comes to a life- and disease course approach to health protection and chronic care, argues Prof Dr Freimut Schliess, Director of Science & Innovation at Profil GmbH.

Prof Dr Freimut Schliess, explores how artificial pancreas systems are revolutionising healthcare for Type 2 diabetes patients.

Prof Dr Freimut Schliess, Director of Science & Innovation at the Profil Institut für Stoffwechselforschung GmbH shares his views on data-based solutions for diabetes.